133921-27-4

Basic information

• Product Name: 4-IODO-3-METHYL-PHENOL
• Synonyms: 4-IODO-3-METHYL-PHENOL;3-methyl-4-iodophenol
• CAS NO: 133921-27-4
• Molecular Formula: C₇H₇IO
• Molecular Weight: 234.03435
• Mol File: 133921-27-4.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 276.673°C at 760 mmHg
• Flash Point: 121.128°C
• Appearance: /
• Density: 1.854g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.647
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 9.46±0.18(Predicted)
• CAS DataBase Reference: 4-IODO-3-METHYL-PHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-IODO-3-METHYL-PHENOL(133921-27-4)
• EPA Substance Registry System: 4-IODO-3-METHYL-PHENOL(133921-27-4)

Safety Data

• Hazardous Substances Data: 133921-27-4(Hazardous Substances Data)

Usage

General Description

4-Iodo-3-methyl-phenol is a chemical compound with the molecular formula C7H7IO. It is a pale yellow crystalline solid that is used as an intermediate in the synthesis of pharmaceuticals and organic compounds. This chemical is known for its antifungal and antimicrobial properties and is often used as an ingredient in topical antiseptics and disinfectants. It is also used in the production of polymers and in organic synthesis. 4-Iodo-3-methyl-phenol is considered to be hazardous if inhaled or ingested and should be handled with care in a controlled laboratory environment.

InChI:InChI=1/C7H7IO/c1-5-4-6(9)2-3-7(5)8/h2-4,9H,1H3

Upstream product

• 108-39-4 3-methyl-phenol 
• 2835-99-6 4-amino-3-methylphenol 

Downstream Products

• 156878-04-5 Methanesulfonic acid 4-iodo-3-methyl-phenyl ester 
• 108-39-4 3-methyl-phenol 
• 845622-63-1 4-iodo-3-methylphenol acetate 
• 845622-69-7 methyl (Z)-2-acetamido-3-(4-acetoxy-2-methylphenyl)-propenoate 
• 845622-75-5 4-acetoxy-N-acetyl-2-methyl-L-tyrosine methyl ester 
• 137378-58-6 (S)-2-((tert-butoxycarbonyl)amino)-3-(4-hydroxy-2-methylphenyl)propanoic acid 
• 845623-01-0 Boc-(2'-monomethyltyrosine)-Pro-Phe-Phe-NH₂ 
• 57556-31-7 4-hydroxy-2-methylbenzoic acid methyl ester 
• 947162-07-4 4-(4-cyanophenoxy)-2-methylphenylboronic acid 
• 906673-24-3 AN₂₇₂₈ 

Relevant articles and documents

METHOD FOR PREPARING CRISABOROLE

The invention relates to a method for preparing Crisaborole of Formula I, comprising using m-methylphenol as the starting material to obtain a target product through a five-step reaction. The starting materials and the raw materials used in each step of the method according to the present invention are cheap and easy to obtain, and the process is simple. The reaction of introducing boron atoms into the benzene ring to form an oxygen boron heterocycle is novel, with high yield and mild conditions, and is suitable for industrial production.

Ultrasonically assisted halogenation of aromatic compounds using isoquinolinium bound hypervalent chromium and tetrabutylammonium halides in PEG-600 solutions under acid free and solvent-free conditions

Isoquinolinium bound Cr(VI) reagents like isoquinolinium dichromate (IQDC) and isoquinolinium chlorochromate (IQCC) have been successfully accomplished as efficient reagents for oxidative halogenation of aromatic compounds using tetrabutylammonium halide (TBAX) as halogenating agents in aqueous polyethylene glycol (PEG-600) under acid free conditions. Tetrabutylammonium bromide (TBAB) has been used for bromination and tetrabutylammonium iodide (TBAI) for iodination. The halogenation reactions that occurred smoothly in 2 to 7 h under conventional conditions are accelerated magnificently under sonication with few minutes (25 to 70 min) of reaction time and fairly good yields. The reactions occurred at moderate temperature under mild and environmentally safe conditions with simple work up.

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.